Literature DB >> 30006125

Breast mass characterization using shear wave elastography and ultrasound.

S Hari1, S B Paul2, R Vidyasagar1, E Dhamija1, A D Adarsh1, S Thulkar1, S Mathur3, V Sreenivas4, S Sharma1, A Srivastava5, V Seenu5, R Prashad5.   

Abstract

PURPOSE: To evaluate the role of SWE in characterizing breast masses and ascertain whether additional use of SWE to ultrasound for evaluating BI-RADS 3 and 4a masses could help reduce long-term follow-up and unnecessary biopsies of these suspicious breast masses.
MATERIALS AND METHODS: This prospective, cross-sectional study was performed between June 2013 and November 2014. All enrolled patients underwent clinical breast examination, ultrasound, SWE and ultrasound-guided core biopsy of the breast mass. Breast Imaging Reporting and Data System (BI-RAD) categories were assigned to breast masses. For qualitative and quantitative variables of SWE, cut-off values for differentiation between benign and malignant breast masses were estimated. Modified BIRADS' (up/downgrading of BIRADS category) was done for BI-RADS 3/4a masses by combining individual SWE parameters and ultrasound findings. Sensitivity, specificity, positive and negative predictive value of modified BI-RADS' and ultrasound BI-RADS were compared.
RESULTS: A total of 119 women (mean age, 42.3±13.6 [SD] years; range: 13-87 years) with a single breast mass each were enrolled. Histopathologically, 57/119 (48%) breast masses were benign and 62 (52%) were malignant. On ultrasound, 42 breast masses were BI-RADS3 and 77 were BI-RADS 4 (4a, n=10; 4b, n=24; 4c, n=43) leading to 96.8% sensitivity and 70.2% specificity. On SWE, benign breast masses were oval/round, homogenous/reasonably homogenous, blue/green with lower elasticity values and malignant breast masses were irregular, inhomogeneous, red/orange with high elasticity values. On modified BI-RADS' using E-color and E-mean/E-max, specificity improved to 78.9% and 75.4% respectively.
CONCLUSION: Addition of SWE to ultrasound improves characterization of BI-RADS 3 and 4a masses. E-max, E-mean and E-color are the most useful SWE parameters to differentiate between malignant and benign breast masses.
Copyright © 2018 Soci showét showé françaises de radiologie. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Breast mass; Image analysis; Shear wave elastography; Ultrasound

Mesh:

Year:  2018        PMID: 30006125     DOI: 10.1016/j.diii.2018.06.002

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  5 in total

1.  Differential diagnosis of B-mode ultrasound Breast Imaging Reporting and Data System category 3-4a lesions in conjunction with shear-wave elastography using conservative and aggressive approaches.

Authors:  Wenxiang Zhi; Aiyu Miao; Chao You; Jin Zhou; Haixian Zhang; Xiaoli Zhu; Yu Wang; Cai Chang
Journal:  Quant Imaging Med Surg       Date:  2022-07

2.  The significance of dual-mode elastography in the diagnosis of breast lesions by physicians with different levels of experience.

Authors:  Sijing Huang; Xiuqin Ye; Keen Yang; Hongtian Tian; Zhimin Ding; Jing Chen; Jinfeng Xu; Fajin Dong
Journal:  Quant Imaging Med Surg       Date:  2022-02

3.  The Value of High-Resolution Ultrasound Combined with Shear-Wave Elastography under Artificial Intelligence Algorithm in Quantitative Evaluation of Skin Thickness in Localized Scleroderma.

Authors:  Kun Jia; Huiying Li; Xiaojing Wu; Caina Xu; Hongyuan Xue
Journal:  Comput Intell Neurosci       Date:  2022-03-04

4.  TGF-β1 and its signal molecules: are they correlated with the elasticity characteristics of breast lesions?

Authors:  Meng Ke Zhang; Bo Wang; Shi Yu Li; Gang Liu; Zhi Li Wang
Journal:  BMC Cancer       Date:  2021-12-15       Impact factor: 4.430

5.  TGF-β1: is it related to the stiffness of breast lesions and can it predict axillary lymph node metastasis?

Authors:  Meng Ke Zhang; Qiu Jing Shang; Shi Yu Li; Bo Wang; Gang Liu; Zhi Li Wang
Journal:  Ann Transl Med       Date:  2021-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.